Latest Breaking News On - Thomas biegi - Page 2 : comparemela.com

Morphosys To Present New Phase 3 MANIFEST-2 Data On Pelabresib In Myelofibrosis In Oral Presentation At 2024 ASCO Annual Meeting

Morphosys To Present New Phase 3 MANIFEST-2 Data On Pelabresib In Myelofibrosis In Oral Presentation At 2024 ASCO Annual Meeting
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesJulia neugebauerThomas biegiKaitlyn nealyConstellation pharmaceuticals incTradegate exchangeCorporate affairsDistribution servicesAmerican society of clinical oncologyNews serviceLymphoma societySys to present new phaseOral presentationClinical oncologyEfficacy dataCombination with ruxolitinib

MorphoSys AG: MorphoSys Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

MorphoSys AG: MorphoSys Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesThomas biegiJean paul kressEamonn nolanJulia neugebauerDennis riedlCorporate affairsCorporate communications investor relationsCompany annual report on formGerman federal financial supervisory authority the bafinExchange commissionManagement boardSupervisory boardNovartis bidcoChief executive officerGerman securities acquisition

EQS-News: MorphoSys Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

EQS-News: MorphoSys AG / Key word(s): Mergers & Acquisitions/Disposal MorphoSys’ Management Board and Supervisory .

United statesThomas biegiJean paul kressJulia neugebauerEamonn nolanCorporate communications investor relationsCompany annual report on formExchange commissionGerman federal financial supervisory authorityCorporate affairsManagement boardSupervisory boardNovartis bidcoChief executive officerGerman securities acquisitionTakeover act

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

EQS-News: MorphoSys AG / Key word: Annual Report MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update 13.03.2024 / 21:01.

United statesThomas biegiMonjuvi minjuviJulia neugebauerJean paul kressEamonn nolanConstellation pharmaceuticals incCorporate communications investor relationsShare of loss associatesEuropean medicines agencyDevelopment rd expensesGerman federal financial supervisory authority the bafinDrug administrationMorphosys group key figuresCorporate affairsLymphoma society

MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2 7 Billion Equity Value

Tafasitamab sold to IncyteNovartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cashShareholders benefit from attractive premium of 94 percent to the one-month volume weighted average price before January 25, 2024Novartis provides ample resources to maximize.

United statesJean paul kressMeagher flomEamonn nolanJulia neugebauerThomas biegiDrug administrationIncyte corporationCompany annual report on formExchange commissionConstellation pharmaceuticals incGerman federal financial supervisory authority bafinGerman federal financial supervisory authority the bafinCorporate affairsXencor incLymphoma society